comparemela.com
Home
Live Updates
Ocugen Announces Positive Clinical Study Update from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA) : comparemela.com
Ocugen Announces Positive Clinical Study Update from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA)
Favorable safety and tolerability profile of OCU400 investigational drug product in RP and LCA subjects to dateClinical study update suggests continued positive trends in Best-Corrected Visual Acuity ...
Related Keywords
Los Angeles ,
California ,
United States ,
Tarun Upadhyay ,
David Boyer ,
Lejla Vajzovic ,
Shankar Musunuri ,
Retina Vitreous Associates Medical Group ,
Ocugen Inc ,
Retina Foundation Of The ,
Duke University School Of Medicine ,
Aboutocugen Inc ,
Keck School Of Medicine Los Angeles ,
Twitter ,
Linkedin ,
Head Of Communications ,
Head Of Research ,
Best Corrected Visual Acuity ,
Multi Luminance Mobility Testing ,
Low Luminance Visual Acuity ,
Retinitis Pigmentosa ,
Chief Executive Officer ,
Chief Scientific Officer ,
Associate Professor ,
Duke Vitreoretinal Fellowship Program ,
Duke Eye Center ,
Duke University School ,
David Birch ,
Scientific Director ,
Retina Foundation ,
Clinical Professor ,
Keck School ,
Medicine Los Angeles ,
Retina Vitreous Associates Medical ,
Markets ,
comparemela.com © 2020. All Rights Reserved.